Sign in Register

Drug class

Interleukin 23 Antagonists

Interleukin-23 antagonists are a therapeutic class of targeted biologic agents designed to disrupt the proinflammatory signaling pathways driven by interleukin-23. Read more about Interleukin 23 Antagonists

13 drugs in this class 4 manufacturers

Related classes & indications

Antirheumatic Agents (Biologic DMARDS)Biologics, antibodies & cell therapy · 170 prescription drugs Immunomodulator, B-Lymphocyte Stimulator (BLyS)-Spec InhibBiologics, antibodies & cell therapy · 38 prescription drugs Moderate To Severe Plaque PsoriasisTop indication · 173 prescription drugs

Showing 1–9 of 13 drugs

Sort

SKYRIZI ON-BODY (risankizumab-rzaa)

INTERLEUKIN 23 ANTAGONISTS · CROHN'S DISEASE ·+3

ABBOTT

SKYRIZI PEN (risankizumab-rzaa)

ANTIPSORIATICS · CROHN'S DISEASE ·+3

ABBOTT

TREMFYA PEN (guselkumab)

ANTIPSORIATICS · CROHN'S DISEASE ·+3

JANSSEN BIOTECH, Inc.

OMVOH MIRIKIZUMAB (docusate sodium)

INTERLEUKIN 23 ANTAGONISTS · CONSTIPATION

Eli Lilly and Company

TREMFYA (guselkumab)

ANTIPSORIATICS · CROHN'S DISEASE ·+3

JANSSEN BIOTECH, Inc.

TREMFYA (guselkumab)

ANTIPSORIATICS · CROHN'S DISEASE ·+3

JANSSEN BIOTECH, Inc.

ILUMYA (tildrakizumab-asmn)

ANTIPSORIATICS · MODERATE TO SEVERE PLAQUE PSORIASIS

SUN PHARMA GLOB

SKYRIZI (risankizumab-rzaa)

ANTIPSORIATICS · CROHN'S DISEASE ·+3

ABBOTT

OMVOH (mirikizumab-mrkz)

INTERLEUKIN 23 ANTAGONISTS · CROHN'S DISEASE ·+1

Eli Lilly and Company

Filter & compare in the drug finder → Opens the drug finder with Interleukin 23 Antagonists preselected. Add indication or manufacturer filters there.

About Interleukin 23 Antagonists.

Interleukin-23 antagonists are a therapeutic class of targeted biologic agents designed to disrupt the proinflammatory signaling pathways driven by interleukin-23.

These agents, primarily monoclonal antibodies such as guselkumab, risankizumab, tildrakizumab, and mirikizumab, selectively bind to the unique p19 subunit of interleukin-23, thereby preventing its interaction with cell-surface receptors and inhibiting downstream inflammatory cascades, particularly the activation and differentiation of T-helper 17 cells.

Clinically, this class is primarily utilized to treat chronic immune-mediated inflammatory disorders, including moderate-to-severe plaque psoriasis, active psoriatic arthritis, and inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.

nih.gov
Interleukin-23 antagonists are a therapeutic class of targeted biologic agents designed to disrupt the proinflammatory signaling pathways driven by interleukin-23 These agents, primarily monoclonal antibodies such as guselkumab, risankizumab, tildrakizumab, and mirikizumab, selectively bind to the unique p19 subunit of interleukin-23, thereby preventing its interaction with cell-surface receptors and inhibiting downstream inflammatory cascades, particularly the activation and differentiation of ...
nih.gov
Interleukin-23 antagonists are a therapeutic class of targeted biologic agents designed to disrupt the proinflammatory signaling pathways driven by interleukin-23 These agents, primarily monoclonal antibodies such as guselkumab, risankizumab, tildrakizumab, and mirikizumab, selectively bind to the unique p19 subunit of interleukin-23, thereby preventing its interaction with cell-surface receptors and inhibiting downstream inflammatory cascades, particularly the activation and differentiation of ...
fda.gov
These agents, primarily monoclonal antibodies such as guselkumab, risankizumab, tildrakizumab, and mirikizumab, selectively bind to the unique p19 subunit of interleukin-23, thereby preventing its interaction with cell-surface receptors and inhibiting downstream inflammatory cascades, particularly the activation and differentiation of T-helper 17 cells Clinically, this class is primarily utilized to treat chronic immune-mediated inflammatory disorders, including moderate-to-severe plaque psorias...
fda.gov
These agents, primarily monoclonal antibodies such as guselkumab, risankizumab, tildrakizumab, and mirikizumab, selectively bind to the unique p19 subunit of interleukin-23, thereby preventing its interaction with cell-surface receptors and inhibiting downstream inflammatory cascades, particularly the activation and differentiation of T-helper 17 cells Clinically, this class is primarily utilized to treat chronic immune-mediated inflammatory disorders, including moderate-to-severe plaque psorias...
fda.gov
These agents, primarily monoclonal antibodies such as guselkumab, risankizumab, tildrakizumab, and mirikizumab, selectively bind to the unique p19 subunit of interleukin-23, thereby preventing its interaction with cell-surface receptors and inhibiting downstream inflammatory cascades, particularly the activation and differentiation of T-helper 17 cells Clinically, this class is primarily utilized to treat chronic immune-mediated inflammatory disorders, including moderate-to-severe plaque psorias...
fda.gov
These agents, primarily monoclonal antibodies such as guselkumab, risankizumab, tildrakizumab, and mirikizumab, selectively bind to the unique p19 subunit of interleukin-23, thereby preventing its interaction with cell-surface receptors and inhibiting downstream inflammatory cascades, particularly the activation and differentiation of T-helper 17 cells Clinically, this class is primarily utilized to treat chronic immune-mediated inflammatory disorders, including moderate-to-severe plaque psorias...